Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2016

Pharma News, 2016

Drug combination shows benefit for men with melanoma
Drug combination shows benefit for men with melanoma
WASHINGTON, March 18 (UPI) -- A drug combination approved last year by the U.
Fangs giving: How snake venom could hold the key to Alzheimer's treatment
Fangs giving: How snake venom could hold the key to Alzheimer's treatment
Melbourne researchers believe snake venom may hold the key to destroying plaques that cause Alzheimer's disease, offering new hope for a drug that could prevent the disease taking hold in newly-di...
Amgen And UCB Announce Positive Top-Line Results From Phase 3 Study Evaluating Romosozumab In Men With Osteoporosis
Amgen And UCB Announce Positive Top-Line Results From Phase 3 Study Evaluating Romosozumab In Men With Osteoporosis
THOUSAND OAKS, Calif.
Pfizer's Xeljanz rheumatoid arthritis drug meets endpoints in ulcerative colitis trials
Pfizer's Xeljanz rheumatoid arthritis drug meets endpoints in ulcerative colitis trials
Pfizer's rheumatoid arthritis drug Xeljanz (tofacitinib) has met primary and key secondary endpoints in two phase trials to treat ulcerative colitis (UC).
Allergan Confirms Generic Abraxane® Patent Challenge
Allergan Confirms Generic Abraxane® Patent Challenge
DUBLIN, March 17, 2016 /PRNewswire/ -- Allergan plc (NYSE.
Express Scripts says U.S. drug spending rose 5.2 percent in 2015
Express Scripts says U.S. drug spending rose 5.2 percent in 2015
U.
Sanofi signs deal worth up to $2.3 billion with DiCE Molecules
Sanofi signs deal worth up to $2.3 billion with DiCE Molecules
French drugmaker Sanofi could pay privately held DiCE Molecules as much as $2.
FDA Approves Evomela
FDA Approves Evomela
HENDERSON, Nev.
FDA Approves Bayer's KOVALTRY® Antihemophilic Factor (Recombinant) for the Treatment of Children and Adults with Hemophilia A
FDA Approves Bayer's KOVALTRY® Antihemophilic Factor (Recombinant) for the Treatment of Children and Adults with Hemophilia A
WHIPPANY, N.
Herpes virus and EBV could be tackled by heart drug
Herpes virus and EBV could be tackled by heart drug
Spironolactone, commonly used in cases of heart failure, has surprised scientists by blocking infection by Epstein-Barr virus, in a breakthrough that could help people with a wide variety of herpes-re...
This new biosensor can diagnose cancer and other diseases on the spot
This new biosensor can diagnose cancer and other diseases on the spot
Spotting the spread of diseases such as cancer in their early stages can make a huge difference to the likelihood of being able to beat them into submission, and scientists in Singapore have developed...
European Medicines Agency to start review of Gilead’s cancer medicine Zydelig
European Medicines Agency to start review of Gilead’s cancer medicine Zydelig
The European Commission has requested the European Medicines Agency (EMA) to start a review of Gilead Science's cancer medicine Zydelig (idelalisib), following concerns over seriou...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand